  |
 |
|
    |
|
|
|
|
      
|
|
The Criteria for the Clinical Use of Intravenous Immunoglobulin (IVIg) in Australia (the Criteria) was developed to assist clinicians and transfusion medicine professionals to identify the conditions and circumstances for which the use of intravenous immunoglobulin (IVIg) is appropriate and funded under the National Blood Agreement. The Criteria supersedes the AHMAC IVIg Guidelines published in 2000.
The information and recommendations represent informed opinion, based where possible upon systematic review of the evidence. In the absence of published evidence, recommendations are based on clinical advice provided to the parties involved in developing the Criteria.
A Quick Reference Guide and Frequently Asked Questions have been developed to accompany the Criteria.
Published copies of the Criteria and the Quick Reference Guide can be obtained from the NBA by completing an order request form online or by facsimile 
.
A clarification of some of the indications within the Criteria was conducted in November 2008 resulting in revisions to the Criteria and associated Quick Reference Guide .
Some indications within the Criteria were out of scope of the Clarification Process which was established to consider existing indications listed in chapters 5 to 7 only. These indications were submitted to the 2010/2011 formal review process.
The Criteria is reviewed three yearly, with the review process commencing two years after the release of each new version, allowing twelve months for consultation and drafting. The 2010 IVIg Criteria Review commenced in March 2010.
For more information please contact the National Blood Authority by email at ivigcriteria@nba.gov.au.
(1.71MB) (221KB) (680KB) (154KB) (518KB) (984KB)
Feedback | Privacy | Copyright | Disclaimer | Contact Us
This page last modified on June 29, 2011
